Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer Clinical research trials and Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer. Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer



Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

For Condition: adenocarcinoma of the prostate,stage 4 prostate cancer,recurrent prostate cancer,stage 3 prostate cancer
Status: Recruiting
Sponsor(s): Burzynski Research Institute ,
Synopsis: RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial studies the effectiveness of antineoplaston therapy in treating patients who have stage III or stage IV prostate cancer.
Details: OBJECTIVES: - Determine the antitumor activity of antineoplaston A10 and AS2-1 capsules in patients with stage III or IV adenocarcinoma of the prostate by determining the proportion of patients who experience an objective response. - Evaluate the adverse effects of and tolerance to this regimen in these patients. OUTLINE: This is an open-label study. Patients receive gradually escalating doses of antineoplaston A10 and antineoplaston AS2-1 capsules 6 to 7 times a day until the maximum tolerated dose is reached. Treatment continues for at least 3 months in the absence of disease progression or unacceptable toxicity. Tumors are measured every 4 months for 2 years, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven stage III or IV adenocarcinoma of the prostate not potentially curable by surgery or radiotherapy - Measurable tumors or tumor markers - No response to antiandrogen withdrawal PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 60-100% Life expectancy: - At least 3 months Hematopoietic: - WBC at least 3000/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 2.5 mg/dL - SGOT no greater than 2 times normal - No hepatic failure Renal: - BUN less than 60 mg/dL - Creatinine no greater than 2.5 mg/dL OR - Creatinine clearance greater than 60 mL/min - Blood ammonia normal - No chronic renal failure Cardiovascular: - No severe heart disease Pulmonary: - No severe lung disease Other: - Fertile patients must use effective contraception during and for 4 weeks after study participation - No serious active infection or fever - No other concurrent serious disease - No other prior or concurrent malignancy within the past 2 years PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 4 weeks since prior immunotherapy and recovered Chemotherapy: - At least 4 weeks since prior chemotherapy and recovered Endocrine therapy: - At least 4 weeks since prior hormonal therapy and recovered - Prior corticosteroids for at least 2 months allowed, but must be on stable or decreasing dose during study participation Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy and recovered Surgery: - See Disease Characteristics - At least 4 weeks since prior surgery and recovered Other: - At least 4 weeks since prior experimental clinical trial - No other concurrent therapy for metastatic disease
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
StanislawBurzynski,  Study Chair,  Burzynski Research Institute

Burzynski Clinic *Recruiting*
Houston,  Texas,  77055-6330
United States
Recruiting Stanislaw  Burzynski 713-335-5697


Additional Information:
Study ID Numbers:  CDR0000066559;  BC-PR-5
Study Start Date: 
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003516

Other Adenocarcinoma Of The Prostate Studies:
1. Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

2. Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

3. Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

4. Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer

5. Rapid Hormone Cycling With Testosterone and Leuprolide Combined With Docetaxel in Treating Patients With Recurrent or Metastatic Adenocarcinoma (Cancer) of the Prostate

Related Studies:

Other adenocarcinoma of the prostate Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Modify your Search

  Other adenocarcinoma of the prostate Clinical Trials
  Other Texas Clinical Trials
  Other Houston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103